FineMark National Bank & Trust’s Supernus Pharmaceuticals SUPN Stock Holding History

FineMark National Bank & Trust’s Portfolio SUPN Stock Details SUPN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q1	–	Sell	-981	Closed	-$25K	–	923
2016 Q4	$25K	Hold	981	–	–	﹤0.01%	786
2016 Q3	$24K	Buy	981 +105	+12%	+$2.38K	﹤0.01%	771
2016 Q2	$18K	Buy	876 +417	+91%	+$7.4K	﹤0.01%	844
2016 Q1	$7K	Hold	459	–	–	﹤0.01%	984
2015 Q4	$6K	Hold	459	–	–	﹤0.01%	1025
2015 Q3	$6K	Sell	459 -508	-53%	-$9.45K	﹤0.01%	1071
2015 Q2	$16K	Buy	+967	New	+$13.8K	﹤0.01%	929

Other funds holding SUPN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

RIM

Ranger Investment Management Dallas, Texas $1.38B AUM 24.55% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

RCAMU

Rothschild & Co Asset Management US Stamford, Connecticut $6.58B AUM 4.5% 1-Year Est. Return

RHJA

Rice Hall James & Associates San Diego, California $1.8B AUM 36.16% 1-Year Est. Return

FineMark National Bank & Trust's SUPN Position: Q1 2017 in Review

FineMark National Bank & Trust sold out of Supernus Pharmaceuticals (SUPN) in Q1 2017, closing a stake of 981 shares — an estimated $25K sold.

FineMark National Bank & Trust first reported a position in SUPN in Q2 2015 and held it in 7 quarters. The position peaked at $25K in Q4 2016. 247 funds tracked by Wall St. Rank hold SUPN as of Q1 2017.

FineMark National Bank & Trust reported no remaining Supernus Pharmaceuticals position as of Q1 2017 after selling out during the quarter.
FineMark National Bank & Trust sold 981 Supernus Pharmaceuticals shares in Q1 2017, an estimated $25K.
FineMark National Bank & Trust first reported a position in Supernus Pharmaceuticals in Q2 2015 and held it in 7 quarters.
FineMark National Bank & Trust's Supernus Pharmaceuticals position peaked at $25K in Q4 2016.
247 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q1 2017.

Based on FineMark National Bank & Trust's 13F filing for Q1 2017, filed 12 May 2017.